Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Tyrosine Kinase Inhibitor;   Drug: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA];   Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials